Gyre Therapeutics, Inc. GYRE Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 95.1%-1.1pp | 95.4%-1.0pp | 95.5%-0.8pp | 95.9%-0.3pp | 96.2%+0.1pp | |
| Operating margin | -0.1%-10.4pp | 9.9%-5.4pp | 11.2%+83.7pp | 9.1%+69.7pp | 10.3%+67.2pp | |
| EBITDA margin | 2.1%-9.8pp | 12%-4.8pp | 13.4%+84.5pp | 11.2%+70.7pp | 12%+67.8pp | |
| Free cash flow margin | 2.6%— | -0.2%— | 2.7%— | —— | —— | |
| Returns | ||||||
| Return on invested capital | -0.1%-19.4pp | 12.8%— | 16.7%— | 13.7%— | 19.3%— | |
| Efficiency | ||||||
| Asset turnover | 0.8×0.0× | 0.8×-0.1× | 0.8×-0.8× | 0.7×-0.9× | 0.8×-0.8× | |
| Inventory turnover | 0.6×0.0× | 0.7×-0.1× | 0.6×— | 0.6×— | 0.6×— | |
| Liquidity | ||||||
| Current ratio | 4.6×+1.0× | 5.6×+2.3× | 6.2×+2.5× | 5.4×+2.0× | 3.6×+0.4× | |
| Quick ratio | 4.1×+0.9× | 5×+2.0× | 5.6×+2.3× | 4.9×+1.8× | 3.2×+0.2× | |
| Cash ratio | 1.9×+1.1× | 2×+1.4× | 2.5×+1.5× | 2.2×+1.1× | 0.8×-0.7× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Net debt / EBITDA | -14.8×-13.7× | -2.6×-2.0× | -2.7×— | -3.1×— | -1.1×— | |
| Per Share | ||||||
| Book value per share | $1.11+66.0% | $1.03+66.0% | $0.98+59.3% | $0.90+51.8% | $0.67+21.0% | |
| Valuation | ||||||
| Market capitalization | $694.58M-4.7% | $680.11M-34.5% | $677.57M-42.2% | $689.9M-32.4% | $722.69M-51.6% | |
| Enterprise value | $657.9M-8.0% | $643.98M-37.4% | $638.33M-44.9% | $654.8M-34.9% | $709.23M-51.5% | |
| Price / sales | 5.9×-1.3× | 5.8×-4.0× | 6.3×-4.8× | 6.8×-2.4× | 7.2×-5.7× | |
| Price / book | 6.9×-3.8× | 6.4×-10.0× | 6.6×-11.9× | 7.5×-9.4× | 10.6×-15.7× | |
| EV / EBITDA | 265.6×+206× | 46.1×-11.9× | 44.6×— | 57.3×— | 58.9×— | |
| EV / sales | 5.6×-1.5× | 5.5×-4.2× | 6×-5.1× | 6.4×-2.6× | 7×-5.6× | |
| Free cash flow yield | 0.4%— | -0%— | 0.4%— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Gyre Therapeutics, Inc.'s profit margins?
- Gyre Therapeutics, Inc. (GYRE) runs a 95.1% gross margin and a -0.1% operating margin, with a 6.3% net margin.
- Where do Gyre Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Gyre Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
